Media stories about Veracyte (NASDAQ:VCYT) have been trending somewhat positive on Monday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.2175922464345 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms recently issued reports on VCYT. Zacks Investment Research lowered Veracyte from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. ValuEngine cut Veracyte from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Piper Jaffray Companies reiterated a “buy” rating on shares of Veracyte in a report on Tuesday, September 12th. BidaskClub upgraded Veracyte from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. Finally, BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of Veracyte in a report on Thursday, August 31st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Veracyte presently has a consensus rating of “Hold” and an average price target of $12.45.
Veracyte (NASDAQ:VCYT) traded down $0.23 during midday trading on Monday, reaching $8.13. The company’s stock had a trading volume of 122,911 shares, compared to its average volume of 112,420. Veracyte has a 1-year low of $5.86 and a 1-year high of $9.80. The company has a debt-to-equity ratio of 0.53, a current ratio of 5.83 and a quick ratio of 5.52.
In other Veracyte news, Chairman Bonnie H. Anderson sold 16,000 shares of Veracyte stock in a transaction on Friday, October 20th. The stock was sold at an average price of $9.41, for a total value of $150,560.00. Following the completion of the sale, the chairman now owns 16,000 shares of the company’s stock, valued at approximately $150,560. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bonnie H. Anderson sold 6,000 shares of Veracyte stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $9.09, for a total value of $54,540.00. Following the completion of the sale, the chief executive officer now directly owns 16,000 shares of the company’s stock, valued at approximately $145,440. The disclosure for this sale can be found here. In the last three months, insiders sold 130,500 shares of company stock valued at $1,085,065. Corporate insiders own 13.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Veracyte (VCYT) Getting Somewhat Favorable News Coverage, Study Finds” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/11/06/veracyte-vcyt-getting-somewhat-favorable-news-coverage-study-finds.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
What are top analysts saying about Veracyte Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Veracyte Inc. and related companies.